Following the repeat diagnostic workup presentation, an expert will lead the discussion, inviting the panel's input on the most appropriate treatment course for this patient.
Cilta-Cel May Outperform Standard Care for Relapsed, Refractory Myeloma
An indirect comparison found that cilta-cel may be better than standard of care for patients with lenalidomise-refractory relapsed/refractory myeloma.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
Talquetamab May Be Underutilized in Relapsed/Refractory Myeloma
A poll of experts revealed that few are utilizing talquetamab for patients with pretreated relapsed/refractory myeloma.
Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape
Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.
Cilta-Cel Continues to Boosts Survival in Pretreated Myeloma
Follow-up from the CARTITUDE-4 trial showed that cilta-cel improved survival over standard of care in pretreated myeloma.
Cilta-Cel Is Safe, Efficacious in Real-World Treatment of Myeloma
Cilta-cel led to high response rates and a promising safety profile in a real-world population of patients with relapsed/refractory myeloma.
Novel ADC Shows Promise in Platinum-Resistant Ovarian Cancer
Chemo Should be Tailored to Decrease Neuropathy in Black Patients
NT-I7 Enhances CAR T-Cell Efficacy in DLBCL
Nurses, Talk AEs, Interstitial Lung Disease, Before Treating With T-DXd